JOHNSON & JOHNSON
Company Stats
- Market Cap
- $638.0B
- as of Sep 30, 2026
- Shares Outstanding
- 2.4B
- Free Float
- 100.0%
Income Statement
- Revenue
- $94.2B
- Net Income
- $26.8B
- Non-cash Impairment
- $204.0M
- FCF Margin, 3Y Avg
- 21.6%
- FCF Margin, Worst Year
- 20.9%
Cash Flow
- Free Cash Flow
- $19.7B
- FCF Yield
- 3.1%
- Owner FCF Yield
- 2.9%
Balance Sheet
- Cash & Equivalents
- $19.7B
Returns & Capital
- Dividends Paid
- $12.4B
- Dividend Yield
- 1.9%
- Dividend Payout, 3Y Avg
- 54.6%
- Share Repurchases
- $6.0B
- Buyback Yield, 3Y Avg
- 0.7%
- SBC, 3Y Avg
- $1.2B
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $94.2B | $19.7B | 20.9% |
| FY2024 | $88.8B | $19.8B | 22.3% |
| FY2023 | $85.2B | $18.2B | 21.4% |
| FY2023 | $80.0B | $17.2B | 21.5% |
| FY2022 | $78.7B | $19.8B | 25.1% |
Annual filing data through FY ended December 28, 2025; shares and float as of November 7, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 18, 2026
Weekly Earnings
Earnings Roundup for Week of Oct. 12, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 29, 2026
Deals
J&J to Buy Firefly Bio in $1 Billion Cash Asset Deal
Earnings Roundup for Week of Oct. 12, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
July 29, 2026
Deals
J&J to Buy Firefly Bio in $1 Billion Cash Asset Deal